Celularity Inc has officially filed its annual report for the fiscal year ending December 31, 2025. This filing is significant as it showcases the company's financial performance and strategic direction in the pharmaceutical preparations sector.
Background
Celularity Inc operates in the pharmaceutical preparations industry, classified under SIC code 2834. The company is listed on the Nasdaq under the ticker symbol CELU. As an emerging growth company, Celularity is committed to maintaining transparency and compliance with regulatory standards.
What the Filing Says
The filing, dated November 10, 2026, indicates that Celularity is adhering to its reporting obligations under the SEC Act of 1934. Specific details regarding financial performance or operational changes were not disclosed in the filing.
Impact
This filing may affect various stakeholders, including investors who are keen on understanding the company's performance and future outlook. Regulatory bodies will also scrutinize the report to ensure compliance with industry standards. Competitors in the pharmaceutical sector will likely keep a close eye on Celularity's developments as they navigate their own strategies.
What's Next
The filing does not say what happens next.
Financial Highlights
The annual report does not provide specific financial figures or metrics for the fiscal year ending December 31, 2025. However, it does confirm that Celularity Inc is committed to transparency and adheres to the SEC Act of 1934, which requires public companies to disclose their financial performance and operational changes.
Company Structure and Governance
Celularity Inc was incorporated in Delaware and operates under the organization name 03 Life Sciences. The company has a Central Index Key (CIK) of 0001752828, which is essential for tracking its filings with the SEC. The filing does not include details about the board of directors or executive compensation, which are typically part of annual reports.
Contact Information
For stakeholders seeking further information, Celularity Inc's business address is 170 Park Ave, Florham Park, NJ 07932. The company can be reached by phone at (908) 768-2170. The report does not provide email contact details or a website link for further inquiries.
Absence of Future Outlook
Notably, the filing does not include any forward-looking statements or projections regarding the company’s strategic plans or anticipated market conditions, which are often included in annual reports to provide insights into future performance.
Read Next
Sven-Olof Lindblad sells shares in Lindblad Expeditions
Zeo Energy CEO Timothy Bridgewater Acquires 107,955 Shares
Manthripragada Vijay Acquires Additional Shares in Onterris
Laws James Acquires Shares in Onterris, Inc. via RSUs
Eightco Holdings CEO Acquires 100,000 Shares of Stock
Eightco CFO Vroman Acquires 15,000 Shares in Stock Transaction





